|
Motor neuron atrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our study demonstrates that vascular regression occurs before motor neuron degeneration in FUS (1-359) mice, and highlights that heterogeneity in responses to novel ALS therapeutics can already be detected in preclinical mouse models of ALS.This article has an associated First Person interview with the joint first authors of the paper.
|
31383794 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
Altogether, these results indicate that miR-663 acts as a potential tumor-promoting miRNA through targeting TUSC2 in ovarian cancer.
|
30944041 |
2019 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MicroRNA-138 is a Prognostic Biomarker for Triple-Negative Breast Cancer and Promotes Tumorigenesis via TUSC2 repression.
|
31481748 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TUSC2 combined with anti-PD-1 induced tumor infiltrating more than NK and CD8<sup>+</sup> T cells and fewer MDSCs and Tregs than each agent alone, both in subcutaneous tumor and in lung metastases.
|
29339375 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Detection of high-grade neoplasia in air-dried cervical PAP smears by a microRNA-based classifier.
|
29328473 |
2018 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because of the role of TUSC2 in regulating immune cells, we assessed TUSC2 efficacy on antitumor immune responses alone and in combination with anti-PD-1 in two <i>Kras</i>-mutant syngeneic mouse lung cancer models.
|
29339375 |
2018 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because of the role of TUSC2 in regulating immune cells, we assessed TUSC2 efficacy on antitumor immune responses alone and in combination with anti-PD-1 in two <i>Kras</i>-mutant syngeneic mouse lung cancer models.
|
29339375 |
2018 |
|
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because of the role of TUSC2 in regulating immune cells, we assessed TUSC2 efficacy on antitumor immune responses alone and in combination with anti-PD-1 in two <i>Kras</i>-mutant syngeneic mouse lung cancer models.
|
29339375 |
2018 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
For this purpose, raw RT-qPCR data for 25 candidate microRNAs, U6 snRNA and human DNA in air-dried PAP smears from 174 women with different cervical cytological diagnoses, 144 of which were HR-HPV-positive [40 negative for intraepithelial lesion or malignancy (NILM), 34 low-grade squamous intraepithelial lesions (L-SIL), 57 high-grade squamous intraepithelial lesions (H-SIL), 43 invasive cancers], were statistically processed.
|
29328473 |
2018 |
|
Secondary malignant neoplasm of lung
|
0.060 |
Biomarker
|
disease |
BEFREE |
TUSC2 combined with anti-PD-1 induced tumor infiltrating more than NK and CD8<sup>+</sup> T cells and fewer MDSCs and Tregs than each agent alone, both in subcutaneous tumor and in lung metastases.
|
29339375 |
2018 |
|
Amyotrophic Lateral Sclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Survival duration (time elapsed from baseline onset until death) is compared on the basis of Bi-PAP initiation threshold (FVC %predict); daily Bi-PAP usage protocol (hours/day); daily cough assist usage (users or non-users); ALS onset type; ALSFRS-R score; and time elapsed from baseline onset until Bi-PAP initiation, using Kruskal-Wallis one-way analysis of variance and Kaplan Meier.
|
30050497 |
2018 |
|
Amyotrophic Lateral Sclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
FUS(1-359) transgenic mice as a model of ALS: pathophysiological and molecular aspects of the proteinopathy.
|
29982879 |
2018 |
|
Sleep Apnea, Obstructive
|
0.050 |
Biomarker
|
disease |
BEFREE |
A small percentage of adult patients with severe obstructive sleep apnea (OSA) has been recognized to be extraordinarily difficult to treat with conventional continuous or Bi-level positive airway pressure (together referred to as PAP) therapy.
|
28822020 |
2018 |
|
Sleep Apnea, Obstructive
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Current Treatment of Comorbid Insomnia and Obstructive Sleep Apnea With CBTI and PAP-Therapy: A Systematic Review.
|
30420826 |
2018 |
|
Human papilloma virus infection
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Urbanization, the number of sex partners, and PAP history appear as risk factors for HPV infection in Han, but not in Mongolian participants.
|
28661048 |
2018 |
|
Sleep Apnea Syndromes
|
0.020 |
Biomarker
|
disease |
BEFREE |
Approaches to diagnosing and treating sleep apnea that emphasized early application of auto-PAP had lower per-patient costs.
|
29066589 |
2018 |
|
Cardiac Arrhythmia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
This case provides support in favor of a bidirectional relationship between SDB and AF and suggests that data available from PAP machines may be useful in serial assessment of SDB status relative to heart rhythm.
|
30373693 |
2018 |
|
Atrial Fibrillation
|
0.010 |
Biomarker
|
disease |
BEFREE |
This case provides support in favor of a bidirectional relationship between SDB and AF and suggests that data available from PAP machines may be useful in serial assessment of SDB status relative to heart rhythm.
|
30373693 |
2018 |
|
Coughing
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Survival duration (time elapsed from baseline onset until death) is compared on the basis of Bi-PAP initiation threshold (FVC %predict); daily Bi-PAP usage protocol (hours/day); daily cough assist usage (users or non-users); ALS onset type; ALSFRS-R score; and time elapsed from baseline onset until Bi-PAP initiation, using Kruskal-Wallis one-way analysis of variance and Kaplan Meier.
|
30050497 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Although PAH was detected only in one patient, there was a marked increase of PAP in our jSLE patients.
|
28704174 |
2018 |
|
Snoring
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
A blinded scorer classified the hypopneas based on two groups of signals: Group 1: positive airway pressure flow (PAP flow), chest and abdominal effort, and snoring; or Group 2: smoothed PAP flow (for blinding amplitude but not flattening visible) and effort (CW-EMG-EF).
|
29734977 |
2018 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Relation betweenTUSC2P, TUSC2 and ESCC prognosis was predicted by survival analysis (n = 56).
|
30219035 |
2018 |
|
Optic Atrophy 1
|
0.010 |
Biomarker
|
disease |
BEFREE |
The PrevOP-PAP-CTRL includes the motivational intervention only.Primary outcome will be OAK symptoms.
|
30021578 |
2018 |
|
X-linked recessive nephrolithiasis with renal failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we provide further evidence of circadian regulation by SAL1-PAP-XRN signalling, thereby affirming a link between molecular timekeeping and abiotic stress response mechanisms.
|
30081763 |
2018 |
|
Neuropathy
|
0.010 |
Biomarker
|
group |
BEFREE |
We conducted immunohistochemistry on dorsal root ganglion (DRG) neurons, high-performance liquid chromatography for functional assays, and pharmacological interventions to alter PAP and A1Rs in mice with RTX neuropathy.
|
29672450 |
2018 |